pharmaphorum

OCTOBER 11, 2020

The phase 3 PENELOPE-B trial was testing the CDK4/6 inhibitor as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant (pre-surgery) chemotherapy, but failed to show an improvement on the main measure of improved disease-free survival (iDFS).

Chemotherapy 52

Chemotherapy FDA 52

Roots Analysis

OCTOBER 4, 2023

During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy.

Chemotherapy 40

Chemotherapy Immunization FDA 40

pharmaphorum

JUNE 8, 2022

Patients also have to undergo lymphodepleting chemotherapy to help prepare the body for the CAR-T cells. With Lunsumio, patients do not have to wait to start treatment and avoid the need for chemotherapy, which can sometimes not be an option at all for people who are frail.

Chemotherapy 105

Chemotherapy FDA 105

pharmaphorum

FEBRUARY 14, 2022

Padcev (enfortumab vedotin) is already approved as a second-line therapy for urothelial carcinoma (UC) after cisplatin chemotherapy and immunotherapy with checkpoint inhibitors, but Seagen and Astellas are working towards earlier use of the drug. billion-a-year product in 2026, according to GlobalData.

Chemotherapy 59

Chemotherapy FDA 59